Medical Devices; Gastroenterology-Urology Devices; Classification of the Nonimplanted Nerve Stimulator for Functional Abdominal Pain Relief, 71142-71144 [2021-27132]
Download as PDF
<![CDATA[
71142
Federal Register / Vol. 86, No. 238 / Wednesday, December 15, 2021 / Rules and Regulations
AIRAC date
State
City
Airport
FDC date
30–Dec–21 ..
SC
Columbia .................
Columbia Metro ........................
1/9048
11/10/21
30–Dec–21
30–Dec–21
30–Dec–21
30–Dec–21
TX
CA
CA
NH
Fredericksburg .........
Riverside ..................
Riverside ..................
Haverhill ...................
Gillespie County .......................
Riverside Muni ..........................
Riverside Muni ..........................
Dean Meml ...............................
1/9053
1/9359
1/9373
1/9780
11/10/21
11/5/21
11/5/21
9/3/21
..
..
..
..
[FR Doc. 2021–27055 Filed 12–14–21; 8:45 am]
BILLING CODE 4910–13–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 876
[Docket No. FDA–2021–N–0583]
Medical Devices; GastroenterologyUrology Devices; Classification of the
Nonimplanted Nerve Stimulator for
Functional Abdominal Pain Relief
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final amendment; final order.
The Food and Drug
Administration (FDA or we) is
classifying the nonimplanted nerve
stimulator for functional abdominal
pain relief into class II (special
controls). The special controls that
apply to the device type are identified
in this order and will be part of the
codified language for the nonimplanted
nerve stimulator for functional
abdominal pain relief’s classification.
We are taking this action because we
have determined that classifying the
device into class II (special controls)
will provide a reasonable assurance of
safety and effectiveness of the device.
We believe this action will also enhance
patients’ access to beneficial innovative
devices.
DATES: This order is effective December
15, 2021. The classification was
applicable on June 7, 2019.
FOR FURTHER INFORMATION CONTACT:
Pamela Scott, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4208, Silver Spring,
MD 20993–0002, 301–796–5433,
PamelaD.Scott@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
khammond on DSKJM1Z7X2PROD with RULES
FDC No.
I. Background
Upon request, FDA has classified the
nonimplanted nerve stimulator for
functional abdominal pain relief as class
II (special controls), which we have
determined will provide a reasonable
VerDate Sep<11>2014
16:21 Dec 14, 2021
Jkt 256001
assurance of safety and effectiveness. In
addition, we believe this action will
enhance patients’ access to beneficial
innovation, by placing the device into a
lower device class than the automatic
class III assignment.
The automatic assignment of class III
occurs by operation of law and without
any action by FDA, regardless of the
level of risk posed by the new device.
Any device that was not in commercial
distribution before May 28, 1976, is
automatically classified as, and remains
within, class III and requires premarket
approval unless and until FDA takes an
action to classify or reclassify the device
(see 21 U.S.C. 360c(f)(1)). We refer to
these devices as ‘‘postamendments
devices’’ because they were not in
commercial distribution prior to the
date of enactment of the Medical Device
Amendments of 1976, which amended
the Federal Food, Drug, and Cosmetic
Act (FD&C Act).
FDA may take a variety of actions in
appropriate circumstances to classify or
reclassify a device into class I or II. We
may issue an order finding a new device
to be substantially equivalent under
section 513(i) of the FD&C Act (21
U.S.C. 360c(i)) to a predicate device that
does not require premarket approval.
We determine whether a new device is
substantially equivalent to a predicate
device by means of the procedures for
premarket notification under section
510(k) of the FD&C Act (21 U.S.C.
360(k)) and part 807 (21 CFR part 807).
FDA may also classify a device
through ‘‘De Novo’’ classification, a
common name for the process
authorized under section 513(f)(2) of the
FD&C Act. Section 207 of the Food and
Drug Administration Modernization Act
of 1997 established the first procedure
for De Novo classification (Pub. L. 105–
115). Section 607 of the Food and Drug
Administration Safety and Innovation
Act modified the De Novo application
process by adding a second procedure
(Pub. L. 112–144). A device sponsor
may utilize either procedure for De
Novo classification.
Under the first procedure, the person
submits a 510(k) for a device that has
not previously been classified. After
receiving an order from FDA classifying
the device into class III under section
513(f)(1) of the FD&C Act, the person
PO 00000
Frm 00014
Fmt 4700
Sfmt 4700
Subject
ILS OR LOC RWY 11, Amdt
15A.
VOR/DME–A, Amdt 3B.
RNAV (GPS) RWY 9, Amdt 2C.
ILS OR LOC RWY 9, Amdt 8D.
RNAV (GPS) RWY 19, Orig.
then requests a classification under
section 513(f)(2).
Under the second procedure, rather
than first submitting a 510(k) and then
a request for classification, if the person
determines that there is no legally
marketed device upon which to base a
determination of substantial
equivalence, that person requests a
classification under section 513(f)(2) of
the FD&C Act.
Under either procedure for De Novo
classification, FDA is required to
classify the device by written order
within 120 days. The classification will
be according to the criteria under
section 513(a)(1) of the FD&C Act.
Although the device was automatically
placed within class III, the De Novo
classification is considered to be the
initial classification of the device.
When FDA classifies a device into
class I or II via the De Novo process, the
device can serve as a predicate for
future devices of that type, including for
510(k)s (see 21 U.S.C. 360c(f)(2)(B)(i)).
As a result, other device sponsors do not
have to submit a De Novo request or
premarket approval application to
market a substantially equivalent device
(see 21 U.S.C. 360c(i), defining
‘‘substantial equivalence’’). Instead,
sponsors can use the less-burdensome
510(k) process, when necessary, to
market their device.
II. De Novo Classification
On October 25, 2018, Innovative
Health Solutions, Inc. submitted a
request for De Novo classification of the
IB-Stim. FDA reviewed the request in
order to classify the device under the
criteria for classification set forth in
section 513(a)(1) of the FD&C Act.
We classify devices into class II if
general controls by themselves are
insufficient to provide reasonable
assurance of safety and effectiveness,
but there is sufficient information to
establish special controls that, in
combination with the general controls,
provide reasonable assurance of the
safety and effectiveness of the device for
its intended use (see 21 U.S.C.
360c(a)(1)(B)). After review of the
information submitted in the request,
we determined that the device can be
classified into class II with the
establishment of special controls. FDA
E:\FR\FM\15DER1.SGM
15DER1
Federal Register / Vol. 86, No. 238 / Wednesday, December 15, 2021 / Rules and Regulations
has determined that these special
controls, in addition to the general
controls, will provide reasonable
assurance of the safety and effectiveness
of the device.
Therefore, on June 7, 2019, FDA
issued an order to the requester
classifying the device into class II. In
this final order, FDA is codifying the
classification of the device by adding 21
CFR 876.5340.1 We have named the
generic type of device nonimplanted
nerve stimulator for functional
abdominal pain relief, and it is
identified as a device that stimulates
nerves remotely from the source of pain
with the intent to relieve functional
71143
abdominal pain. This generic type of
device does not include devices
designed to relieve pelvic pain.
FDA has identified the following risks
to health associated specifically with
this type of device and the measures
required to mitigate these risks in table
1.
TABLE 1—NONIMPLANTED NERVE STIMULATOR FOR FUNCTIONAL ABDOMINAL PAIN RELIEF RISKS AND MITIGATION
MEASURES
Identified risks
Mitigation measures
Adverse tissue reaction ......................................
Electrical, mechanical, or thermal hazards leading to user discomfort or injury.
Biocompatibility evaluation, and Labeling.
Electromagnetic compatibility testing; Electrical, mechanical, and thermal safety testing; Nonclinical performance testing; Software verification, validation and hazard analysis; and Labeling.
Sterility testing, Shelf life testing, and Labeling.
Infection ..............................................................
FDA has determined that special
controls, in combination with the
general controls, address these risks to
health and provide reasonable assurance
of safety and effectiveness. In order for
a device to fall within this classification,
and thus avoid automatic classification
in class III, it would have to comply
with the special controls named in this
final order. The necessary special
controls appear in the regulation
codified by this order. This device is
subject to premarket notification
requirements under section 510(k).
At the time of classification,
nonimplanted nerve stimulators for
functional abdominal pain relief are for
prescription use only. Prescription
devices are exempt from the
requirement for adequate directions for
use for the layperson under section
502(f)(1) of the FD&C Act (21 U.S.C.
352(f)(1)) and 21 CFR 801.5, as long as
the conditions of 21 CFR 801.109 are
met.
khammond on DSKJM1Z7X2PROD with RULES
III. Analysis of Environmental Impact
The Agency has determined under 21
CFR 25.34(b) that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501–3521). The
collections of information in the
guidance document ‘‘De Novo
Classification Process (Evaluation of
Automatic Class III Designation)’’ have
been approved under OMB control
number 0910–0844; the collections of
information in 21 CFR part 814,
subparts A through E, regarding
premarket approval, have been
approved under OMB control number
0910–0231; the collections of
information in part 807, subpart E,
regarding premarket notification
submissions, have been approved under
OMB control number 0910–0120; the
collections of information in 21 CFR
part 820, regarding quality system
regulation, have been approved under
OMB control number 0910–0073; and
the collections of information in 21 CFR
part 801, regarding labeling, have been
approved under OMB control number
0910–0485.
List of Subjects in 21 CFR Part 876
Medical devices.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs, 21 CFR part 876 is
amended as follows:
IV. Paperwork Reduction Act of 1995
This final order establishes special
controls that refer to previously
approved collections of information
found in other FDA regulations and
guidance. These collections of
information are subject to review by the
■
1 FDA notes that the ‘‘ACTION’’ caption for this
final order is styled as ‘‘Final amendment; final
order,’’ rather than ‘‘Final order.’’ Beginning in
December 2019, this editorial change was made to
indicate that the document ‘‘amends’’ the Code of
Federal Regulations. The change was made in
accordance with the Office of Federal Register’s
(OFR) interpretations of the Federal Register Act (44
VerDate Sep<11>2014
16:21 Dec 14, 2021
Jkt 256001
PART 876—GASTROENTEROLOGY–
UROLOGY DEVICES
1. The authority citation for part 876
continues to read as follows:
Authority: 21 U.S.C. 351, 360, 360c, 360e,
360j, 360l, 371.
PO 00000
Frm 00015
Fmt 4700
Sfmt 4700
2. Add § 876.5340 to subpart F to read
as follows:
■
§ 876.5340 Nonimplanted nerve stimulator
for functional abdominal pain relief.
(a) Identification. A nonimplanted
nerve stimulator for functional
abdominal pain relief is a device that
stimulates nerves remotely from the
source of pain with the intent to relieve
functional abdominal pain. This generic
type of device does not include devices
designed to relieve pelvic pain.
(b) Classification. Class II (special
controls). The special controls for this
device are:
(1) The patient-contacting
components of the device must be
demonstrated to be biocompatible.
(2) Electromagnetic compatibility and
electrical, mechanical, and thermal
safety testing must be performed.
(3) Electrical performance testing of
the device and electrodes must be
conducted to validate the specified
electrical output and duration of
stimulation of the device.
(4) Software verification, validation,
and hazard analysis must be performed.
(5) Sterility testing of the
percutaneous components of the device
must be performed.
(6) Shelf life testing must be
performed to demonstrate continued
sterility, package integrity, and device
functionality over the labeled shelf life.
(7) Labeling must include the
following:
(i) A detailed summary of the device
technical parameters;
(ii) A warning stating that the device
is only for use on clean, intact skin;
U.S.C. chapter 15), its implementing regulations (1
CFR 5.9 and parts 21 and 22), and the Document
Drafting Handbook.
E:\FR\FM\15DER1.SGM
15DER1
71144
Federal Register / Vol. 86, No. 238 / Wednesday, December 15, 2021 / Rules and Regulations
(iii) Instructions for use, including
placement of the device on the patient;
and
(iv) A shelf life.
Dated: December 9, 2021.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2021–27132 Filed 12–14–21; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 876
[Docket No. FDA–2021–N–0590]
Medical Devices; GastroenterologyUrology Devices; Classification of the
Endoscopic Transhepatic Venous
Access Needle
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final amendment; final order.
The Food and Drug
Administration (FDA or we) is
classifying the endoscopic transhepatic
venous access needle into class II
(special controls). The special controls
that apply to the device type are
identified in this order and will be part
of the codified language for the
endoscopic transhepatic venous access
needle’s classification. We are taking
this action because we have determined
that classifying the device into class II
(special controls) will provide a
reasonable assurance of safety and
effectiveness of the device. We believe
this action will also enhance patients’
access to beneficial innovative devices.
DATES: This order is effective December
15, 2021. The classification was
applicable on November 20, 2019.
FOR FURTHER INFORMATION CONTACT:
Thelma Valdes, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 2610, Silver Spring,
MD 20993–0002, 301–796–9621,
Thelma.Valdes@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
khammond on DSKJM1Z7X2PROD with RULES
I. Background
Upon request, FDA has classified the
endoscopic transhepatic venous access
needle as class II (special controls),
which we have determined will provide
a reasonable assurance of safety and
effectiveness. In addition, we believe
this action will enhance patients’ access
to beneficial innovation.
The automatic assignment of class III
occurs by operation of law and without
VerDate Sep<11>2014
16:21 Dec 14, 2021
Jkt 256001
any action by FDA, regardless of the
level of risk posed by the new device.
Any device that was not in commercial
distribution before May 28, 1976, is
automatically classified as, and remains
within, class III and requires premarket
approval unless and until FDA takes an
action to classify or reclassify the device
(see 21 U.S.C. 360c(f)(1)). We refer to
these devices as ‘‘postamendments
devices’’ because they were not in
commercial distribution prior to the
date of enactment of the Medical Device
Amendments of 1976, which amended
the Federal Food, Drug, and Cosmetic
Act (FD&C Act).
FDA may take a variety of actions in
appropriate circumstances to classify or
reclassify a device into class I or II. We
may issue an order finding a new device
to be substantially equivalent under
section 513(i) of the FD&C Act (see 21
U.S.C. 360c(i)) to a predicate device that
does not require premarket approval.
We determine whether a new device is
substantially equivalent to a predicate
by means of the procedures for
premarket notification under section
510(k) of the FD&C Act (21 U.S.C.
360(k)) and part 807 (21 CFR part 807).
FDA may also classify a device
through ‘‘De Novo’’ classification, a
common name for the process
authorized under section 513(f)(2) of the
FD&C Act. Section 207 of the Food and
Drug Administration Modernization Act
of 1997 established the first procedure
for De Novo classification (Pub. L. 105–
115). Section 607 of the Food and Drug
Administration Safety and Innovation
Act modified the De Novo application
process by adding a second procedure
(Pub. L. 112–144). A device sponsor
may utilize either procedure for De
Novo classification.
Under the first procedure, the person
submits a 510(k) for a device that has
not previously been classified. After
receiving an order from FDA classifying
the device into class III under section
513(f)(1) of the FD&C Act, the person
then requests a classification under
section 513(f)(2).
Under the second procedure, rather
than first submitting a 510(k) and then
a request for classification, if the person
determines that there is no legally
marketed device upon which to base a
determination of substantial
equivalence, that person requests a
classification under section 513(f)(2) of
the FD&C Act.
Under either procedure for De Novo
classification, FDA is required to
classify the device by written order
within 120 days. The classification will
be according to the criteria under
section 513(a)(1) of the FD&C Act.
Although the device was automatically
PO 00000
Frm 00016
Fmt 4700
Sfmt 4700
placed within class III, the De Novo
classification is considered to be the
initial classification of the device.
We believe this De Novo classification
will enhance patients’ access to
beneficial innovation. When FDA
classifies a device into class I or II via
the De Novo process, the device can
serve as a predicate for future devices of
that type, including for 510(k)’s (see 21
U.S.C. 360c(f)(2)(B)(i)). As a result, other
device sponsors do not have to submit
a De Novo request or premarket
approval application in order to market
a substantially equivalent device (see 21
U.S.C. 360c(i), defining ‘‘substantial
equivalence’’). Instead, sponsors can use
the less-burdensome 510(k) process,
when necessary, to market their device.
II. De Novo Classification
On November 19, 2018, Cook Ireland
Ltd. submitted a request for De Novo
classification of the EchoTip® InsightTM
Portosystemic Pressure Gradient
Measuring System. FDA reviewed the
request in order to classify the device
under the criteria for classification set
forth in section 513(a)(1) of the FD&C
Act.
We classify devices into class II if
general controls by themselves are
insufficient to provide reasonable
assurance of safety and effectiveness,
but there is sufficient information to
establish special controls that, in
combination with the general controls,
provide reasonable assurance of the
safety and effectiveness of the device for
its intended use (see 21 U.S.C.
360c(a)(1)(B)). After review of the
information submitted in the request,
we determined that the device can be
classified into class II with the
establishment of special controls. FDA
has determined that these special
controls, in addition to the general
controls, will provide reasonable
assurance of the safety and effectiveness
of the device.
Therefore, on November 20, 2019,
FDA issued an order to the requester
classifying the device into class II. FDA
is codifying the classification of the
device by adding 21 CFR 876.1050. 1 We
have named the generic type of device
Endoscopic transhepatic venous access
needle, and it is identified as a device
that is inserted through the liver into the
1 FDA notes that the ‘‘ACTION’’ caption for this
final order is styled as ‘‘Final amendment; final
order,’’ rather than ‘‘Final order.’’ Beginning in
December 2019, this editorial change was made to
indicate that the document ‘‘amends’’ the Code of
Federal Regulations. The change was made in
accordance with the Office of Federal Register’s
(OFR) interpretations of the Federal Register Act (44
U.S.C. chapter 15), its implementing regulations (1
CFR 5.9 and parts 21 and 22), and the Document
Drafting Handbook.
E:\FR\FM\15DER1.SGM
15DER1
]]>Agencies
[Federal Register Volume 86, Number 238 (Wednesday, December 15, 2021)]
[Rules and Regulations]
[Pages 71142-71144]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-27132]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 876
[Docket No. FDA-2021-N-0583]
Medical Devices; Gastroenterology-Urology Devices; Classification
of the Nonimplanted Nerve Stimulator for Functional Abdominal Pain
Relief
AGENCY: Food and Drug Administration, HHS.
ACTION: Final amendment; final order.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is classifying
the nonimplanted nerve stimulator for functional abdominal pain relief
into class II (special controls). The special controls that apply to
the device type are identified in this order and will be part of the
codified language for the nonimplanted nerve stimulator for functional
abdominal pain relief's classification. We are taking this action
because we have determined that classifying the device into class II
(special controls) will provide a reasonable assurance of safety and
effectiveness of the device. We believe this action will also enhance
patients' access to beneficial innovative devices.
DATES: This order is effective December 15, 2021. The classification
was applicable on June 7, 2019.
FOR FURTHER INFORMATION CONTACT: Pamela Scott, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4208, Silver Spring, MD 20993-0002, 301-796-5433,
[email protected].
SUPPLEMENTARY INFORMATION:
I. Background
Upon request, FDA has classified the nonimplanted nerve stimulator
for functional abdominal pain relief as class II (special controls),
which we have determined will provide a reasonable assurance of safety
and effectiveness. In addition, we believe this action will enhance
patients' access to beneficial innovation, by placing the device into a
lower device class than the automatic class III assignment.
The automatic assignment of class III occurs by operation of law
and without any action by FDA, regardless of the level of risk posed by
the new device. Any device that was not in commercial distribution
before May 28, 1976, is automatically classified as, and remains
within, class III and requires premarket approval unless and until FDA
takes an action to classify or reclassify the device (see 21 U.S.C.
360c(f)(1)). We refer to these devices as ``postamendments devices''
because they were not in commercial distribution prior to the date of
enactment of the Medical Device Amendments of 1976, which amended the
Federal Food, Drug, and Cosmetic Act (FD&C Act).
FDA may take a variety of actions in appropriate circumstances to
classify or reclassify a device into class I or II. We may issue an
order finding a new device to be substantially equivalent under section
513(i) of the FD&C Act (21 U.S.C. 360c(i)) to a predicate device that
does not require premarket approval. We determine whether a new device
is substantially equivalent to a predicate device by means of the
procedures for premarket notification under section 510(k) of the FD&C
Act (21 U.S.C. 360(k)) and part 807 (21 CFR part 807).
FDA may also classify a device through ``De Novo'' classification,
a common name for the process authorized under section 513(f)(2) of the
FD&C Act. Section 207 of the Food and Drug Administration Modernization
Act of 1997 established the first procedure for De Novo classification
(Pub. L. 105-115). Section 607 of the Food and Drug Administration
Safety and Innovation Act modified the De Novo application process by
adding a second procedure (Pub. L. 112-144). A device sponsor may
utilize either procedure for De Novo classification.
Under the first procedure, the person submits a 510(k) for a device
that has not previously been classified. After receiving an order from
FDA classifying the device into class III under section 513(f)(1) of
the FD&C Act, the person then requests a classification under section
513(f)(2).
Under the second procedure, rather than first submitting a 510(k)
and then a request for classification, if the person determines that
there is no legally marketed device upon which to base a determination
of substantial equivalence, that person requests a classification under
section 513(f)(2) of the FD&C Act.
Under either procedure for De Novo classification, FDA is required
to classify the device by written order within 120 days. The
classification will be according to the criteria under section
513(a)(1) of the FD&C Act. Although the device was automatically placed
within class III, the De Novo classification is considered to be the
initial classification of the device.
When FDA classifies a device into class I or II via the De Novo
process, the device can serve as a predicate for future devices of that
type, including for 510(k)s (see 21 U.S.C. 360c(f)(2)(B)(i)). As a
result, other device sponsors do not have to submit a De Novo request
or premarket approval application to market a substantially equivalent
device (see 21 U.S.C. 360c(i), defining ``substantial equivalence'').
Instead, sponsors can use the less-burdensome 510(k) process, when
necessary, to market their device.
II. De Novo Classification
On October 25, 2018, Innovative Health Solutions, Inc. submitted a
request for De Novo classification of the IB-Stim. FDA reviewed the
request in order to classify the device under the criteria for
classification set forth in section 513(a)(1) of the FD&C Act.
We classify devices into class II if general controls by themselves
are insufficient to provide reasonable assurance of safety and
effectiveness, but there is sufficient information to establish special
controls that, in combination with the general controls, provide
reasonable assurance of the safety and effectiveness of the device for
its intended use (see 21 U.S.C. 360c(a)(1)(B)). After review of the
information submitted in the request, we determined that the device can
be classified into class II with the establishment of special controls.
FDA
[[Page 71143]]
has determined that these special controls, in addition to the general
controls, will provide reasonable assurance of the safety and
effectiveness of the device.
Therefore, on June 7, 2019, FDA issued an order to the requester
classifying the device into class II. In this final order, FDA is
codifying the classification of the device by adding 21 CFR
876.5340.\1\ We have named the generic type of device nonimplanted
nerve stimulator for functional abdominal pain relief, and it is
identified as a device that stimulates nerves remotely from the source
of pain with the intent to relieve functional abdominal pain. This
generic type of device does not include devices designed to relieve
pelvic pain.
---------------------------------------------------------------------------
\1\ FDA notes that the ``ACTION'' caption for this final order
is styled as ``Final amendment; final order,'' rather than ``Final
order.'' Beginning in December 2019, this editorial change was made
to indicate that the document ``amends'' the Code of Federal
Regulations. The change was made in accordance with the Office of
Federal Register's (OFR) interpretations of the Federal Register Act
(44 U.S.C. chapter 15), its implementing regulations (1 CFR 5.9 and
parts 21 and 22), and the Document Drafting Handbook.
---------------------------------------------------------------------------
FDA has identified the following risks to health associated
specifically with this type of device and the measures required to
mitigate these risks in table 1.
Table 1--Nonimplanted Nerve Stimulator for Functional Abdominal Pain
Relief Risks and Mitigation Measures
------------------------------------------------------------------------
Identified risks Mitigation measures
------------------------------------------------------------------------
Adverse tissue reaction...... Biocompatibility evaluation, and
Labeling.
Electrical, mechanical, or Electromagnetic compatibility testing;
thermal hazards leading to Electrical, mechanical, and thermal
user discomfort or injury. safety testing; Non-clinical performance
testing; Software verification,
validation and hazard analysis; and
Labeling.
Infection.................... Sterility testing, Shelf life testing,
and Labeling.
------------------------------------------------------------------------
FDA has determined that special controls, in combination with the
general controls, address these risks to health and provide reasonable
assurance of safety and effectiveness. In order for a device to fall
within this classification, and thus avoid automatic classification in
class III, it would have to comply with the special controls named in
this final order. The necessary special controls appear in the
regulation codified by this order. This device is subject to premarket
notification requirements under section 510(k).
At the time of classification, nonimplanted nerve stimulators for
functional abdominal pain relief are for prescription use only.
Prescription devices are exempt from the requirement for adequate
directions for use for the layperson under section 502(f)(1) of the
FD&C Act (21 U.S.C. 352(f)(1)) and 21 CFR 801.5, as long as the
conditions of 21 CFR 801.109 are met.
III. Analysis of Environmental Impact
The Agency has determined under 21 CFR 25.34(b) that this action is
of a type that does not individually or cumulatively have a significant
effect on the human environment. Therefore, neither an environmental
assessment nor an environmental impact statement is required.
IV. Paperwork Reduction Act of 1995
This final order establishes special controls that refer to
previously approved collections of information found in other FDA
regulations and guidance. These collections of information are subject
to review by the Office of Management and Budget (OMB) under the
Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3521). The collections
of information in the guidance document ``De Novo Classification
Process (Evaluation of Automatic Class III Designation)'' have been
approved under OMB control number 0910-0844; the collections of
information in 21 CFR part 814, subparts A through E, regarding
premarket approval, have been approved under OMB control number 0910-
0231; the collections of information in part 807, subpart E, regarding
premarket notification submissions, have been approved under OMB
control number 0910-0120; the collections of information in 21 CFR part
820, regarding quality system regulation, have been approved under OMB
control number 0910-0073; and the collections of information in 21 CFR
part 801, regarding labeling, have been approved under OMB control
number 0910-0485.
List of Subjects in 21 CFR Part 876
Medical devices.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs, 21 CFR part
876 is amended as follows:
PART 876--GASTROENTEROLOGY-UROLOGY DEVICES
0
1. The authority citation for part 876 continues to read as follows:
Authority: 21 U.S.C. 351, 360, 360c, 360e, 360j, 360l, 371.
0
2. Add Sec. 876.5340 to subpart F to read as follows:
Sec. 876.5340 Nonimplanted nerve stimulator for functional abdominal
pain relief.
(a) Identification. A nonimplanted nerve stimulator for functional
abdominal pain relief is a device that stimulates nerves remotely from
the source of pain with the intent to relieve functional abdominal
pain. This generic type of device does not include devices designed to
relieve pelvic pain.
(b) Classification. Class II (special controls). The special
controls for this device are:
(1) The patient-contacting components of the device must be
demonstrated to be biocompatible.
(2) Electromagnetic compatibility and electrical, mechanical, and
thermal safety testing must be performed.
(3) Electrical performance testing of the device and electrodes
must be conducted to validate the specified electrical output and
duration of stimulation of the device.
(4) Software verification, validation, and hazard analysis must be
performed.
(5) Sterility testing of the percutaneous components of the device
must be performed.
(6) Shelf life testing must be performed to demonstrate continued
sterility, package integrity, and device functionality over the labeled
shelf life.
(7) Labeling must include the following:
(i) A detailed summary of the device technical parameters;
(ii) A warning stating that the device is only for use on clean,
intact skin;
[[Page 71144]]
(iii) Instructions for use, including placement of the device on
the patient; and
(iv) A shelf life.
Dated: December 9, 2021.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2021-27132 Filed 12-14-21; 8:45 am]
BILLING CODE 4164-01-P
